The most notable one, ADRB1, is the target of cardiovascular and glaucoma drugs, including the broad class of glaucoma drugs targeting the beta-adrenergic receptor antagonists, or beta-blockers, known to lower IOP. This evidence concerns the gene ADRB1 and glaucoma.